Plants derived therapeutic strategies targeting chronic respiratory diseases: Chemical and immunological perspective

Prasher, Parteek; Sharma, Mousmee; Mehta, Meenu; Paudel, Keshav Raj; Satija, Saurabh; Chellappan, Dinesh Kumar; Dureja, Harish; Gupta, Gaurav; Tambuwala, Murtaza M.; Negi, Poonam; Wich, Peter; Hansbro, Philip M.; Dua, Kamal

doi:10.1016/j.cbi.2020.109125

Cited by 47 publications

(12 citation statements)

References 133 publications

(127 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, this issue may be addressed effectively by means of medicinal plant products. Medicinal plants possess the properties of having relatively lesser side effects and are cost effective in nature, due to which, they boast a potential advantage to address the challenges posed by the existing anticancer drugs (Prasher et al., 2020).…”

Section: Introductionmentioning

confidence: 99%

Anti‐inflammatory and anticancer activities of Naringenin‐loaded liquid crystalline nanoparticles in vitro

et al. 2020

Self Cite

View full text Add to dashboard Cite

In this study, we had developed Naringenin-loaded liquid crystalline nanoparticles (LCNs) and investigated the anti-inflammatory and anticancer activities of Naringenin-LCNs against human airway epithelium-derived basal cells (BCi-NS1.1) and human lung epithelial carcinoma (A549) cell lines, respectively. The anti-inflammatory potential of Naringenin-LCNs evaluated by qPCR revealed a decreased expression of IL-6, IL-8, IL-1β, and TNF-α in lipopolysaccharide-induced BCi-NS1.1 cells. The activity of LCNs was comparable to the positive control drug Fluticasone propionate (10 nM). The anticancer activity was studied by evaluating the antiproliferative (MTT and trypan blue assays), antimigratory (scratch wound healing assay, modified Boyden chamber assay, and immunoblot), and anticolony formation activity in A549 cells. Naringenin LCNs showed promising antiproliferative, antimigratory, and anticolony formation activities in A549 cells, in vitro. Therefore, based on our observations and results, we conclude that Naringenin-LCNs may be employed as a potential therapy-based intervention to ameliorate airway inflammation and to inhibit the progression of lung cancer. Practical applications Naringenin was encapsulated into liquid crystalline nanoparticles, thus, attributing to their sustained-release nature. In addition, Naringenin-loaded LCNs efficiently reduced the levels of pro-inflammatory markers, namely, IL-1β, IL-6, TNF-α, and IL-8. In addition, the Naringenin-loaded LCNs also possess potent anticancer activity, when tested in the A549 cell line, as revealed by the inhibition of proliferation and migration of cells. They also attenuated colony formation and induced apoptosis in the A549 cells. The findings from our study could form the basis for future research that may be translated into an in vivo model to validate the possible therapeutic alternative for lung cancer using Naringenin-loaded LCNs. In addition, the applications of

show abstract

Section: Introductionmentioning

confidence: 99%

Anti‐inflammatory and anticancer activities of Naringenin‐loaded liquid crystalline nanoparticles in vitro

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…In recent years, an increasing number of studies have shown that flavonoids from traditional Chinese medicine (TCM) have certain protective effect on COPD [ 11 – 13 ]. Although there have been many research studies on flavonoids in treating COPD, the mechanisms of action of flavonoids are still not totally clear and few securable reviews illustrate the comprehensive and multiple pharmacological effects of flavonoids on COPD.…”

Section: Introductionmentioning

confidence: 99%

Advances in Pharmacological Actions and Mechanisms of Flavonoids from Traditional Chinese Medicine in Treating Chronic Obstructive Pulmonary Disease

Yang

Jin

Jiao

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a common respiratory disease with high morbidity and mortality. The conventional therapies remain palliative and have various undesired effects. Flavonoids from traditional Chinese medicine (TCM) have been proved to exert protective effects on COPD. This review aims to illuminate the poly-pharmacological properties of flavonoids in treating COPD based on laboratory evidences and clinical data and points out possible molecular mechanisms. Animal/laboratory studies and randomised clinical trials about administration of flavonoids from TCM for treating COPD from January 2010 to October 2020 were identified and collected, with the following terms: chronic obstructive pulmonary disease or chronic respiratory disease or inflammatory lung disease, and flavonoid or nature product or traditional Chinese medicine. Pharmacokinetic studies and external application treatment were excluded. A total of 15 flavonoid compounds were listed. Flavonoids could inhibit inflammation, oxidative stress, and cellular senescence, restore corticosteroid sensitivity, improve pulmonary histology, and boost pulmonary function through regulating multiple targets and signaling pathways, which manifest that flavonoids are a group of promising natural products for COPD. Nevertheless, most studies remain in the research phase of animal testing, and further clinical applications should be carried out.

show abstract

“…The application of novel drug delivery systems is gaining popularity for the treatment of various chronic lung diseases, including asthma (Mehta et al 2020a;Mehta et al 2020b;Prasher et al 2020). These include nanoparticle-based drug delivery, dry powder inhalers, micelle pharmacosomes, liposomes, dendrimers, and antibody-mediated drug delivery systems (Lanza et al 2017).…”

Section: Novel Drug Delivery Systemsmentioning

confidence: 99%

Emerging concepts and directed therapeutics for the management of asthma: regulating the regulators

et al. 2020

Self Cite

View full text Add to dashboard Cite

Asthma is a common, heterogeneous and serious disease, its' prevalence has steadily risen in most parts of the world, and the condition is often inadequately controlled in many patients.Hence, there is a major need for new therapeutic approaches. Mild-to-moderate asthma is considered a T-helper cell type-2-mediated inflammatory disorder that develops due to abnormal immune responses to otherwise innocuous allergens. Prolonged exposure to allergens and persistent inflammation results in myofibroblast infiltration and airway remodelling with mucus hypersecretion, airway smooth muscle hypertrophy, and excess collagen deposition.The airways become hyper-responsive to provocation resulting in the characteristic wheezing and obstructed airflow experienced by patients. Extensive research has progressed the understanding of the underlying mechanisms and the development of new treatments for the management of asthma. Here, we review the basis of the disease, covering new areas such as the role of vascularisation and microRNAs, as well as associated potential therapeutic interventions utilising reports from animal and human studies. We also cover novel drug delivery strategies that are being developed to enhance therapeutic efficacy and patient compliance. Potential avenues to explore to improve the future of asthma management are highlighted.

show abstract

Plants derived therapeutic strategies targeting chronic respiratory diseases: Chemical and immunological perspective

Cited by 47 publications

References 133 publications

Anti‐inflammatory and anticancer activities of Naringenin‐loaded liquid crystalline nanoparticles in vitro

Anti‐inflammatory and anticancer activities of Naringenin‐loaded liquid crystalline nanoparticles in vitro

Advances in Pharmacological Actions and Mechanisms of Flavonoids from Traditional Chinese Medicine in Treating Chronic Obstructive Pulmonary Disease

Emerging concepts and directed therapeutics for the management of asthma: regulating the regulators

Contact Info

Product

Resources

About